Advertisement
| car t cell therapy lupus trial: HIV-1 Latency Guido Silvestri, Mathias Lichterfeld, 2018-10-11 This volume summarizes recent advances in understanding the mechanisms of HIV-1 latency, in characterizing residual viral reservoirs, and in developing targeted interventions to reduce HIV-1 persistence during antiretroviral therapy. Specific chapters address the molecular mechanisms that govern and regulate HIV-1 transcription and latency; assays and technical approaches to quantify viral reservoirs in humans and animal models; the complex interchange between viral reservoirs and the host immune system; computational strategies to model viral reservoir dynamics; and the development of therapeutic approaches that target viral reservoir cells. With contributions from an interdisciplinary group of investigators that cover a broad spectrum of subjects, from molecular virology to proof-of-principle clinical trials, this book is a valuable resource for basic scientists, translational investigators, infectious-disease physicians, individuals living with HIV/AIDS and the general public. |
| car t cell therapy lupus trial: Pediatric Neuro-oncology Katrin Scheinemann, Eric Bouffet, 2015-03-26 “The editors...have done an outstanding job of presenting...complex information in a lucid manner – this book is a must-read for the global community of aspiring students and neuro-oncology practitioners.” Amar Gajjar, MD in the Foreword This is a succinct introduction to pediatric neuro-oncology. It summarizes the key advances in molecular biology that have helped transform this rapidly evolving field and provides up-to-date coverage of major and emerging treatment modalities as well as supportive care. Separate chapters present each kind of pediatric brain cancer and its diagnosis and treatment. As more children survive brain cancer, the importance of quality of life issues and helping survivors to cope with the neuropsychological impact and long-term effects of current therapies has come into sharper focus; these topics are also addressed in the book, as are palliative care and pediatric neuro-oncology in countries with limited resources. The book is aimed at trainees and practitioners who seek an up-to-date text in pediatric neuro-oncology that is both comprehensive and concise. |
| car t cell therapy lupus trial: The Lupus Encyclopedia Donald E. Thomas Jr., 2023-09-05 Now completely updated! The best-selling, most comprehensive guide to lupus, its complications, and management. Lupus is an autoimmune disease that can attack any body organ. It is three times more common in the United States today than it was in the 1980s, so there is an increased need for accurate, practical information on this potentially devastating disease. Lupus expert and clinician Donald E. Thomas, Jr., MD, provides all the helpful information patients need so they can understand and treat this disease. Highlighting amazing advancements in the diagnosis and treatment of lupus, this edition includes new and expanded information on: • The latest FDA-approved medications • How lupus affects different body parts • Advanced labs that improve lupus diagnosis and treatment • The role of the microbiome and anti-inflammatory diets • Updated recommendations for those who are pregnant or breastfeeding • Childhood-onset lupus • The interaction between COVID-19 and lupus • Non-drug treatments, complementary medicine, and medical cannabis The gold standard since it was first published and carefully reviewed by experts in the field, the latest edition of The Lupus Encyclopedia is essential for patients, health care providers, and families. Bonus content on insurance issues and information about working with lupus and disability is also available online. Endorsed by The Lupus Foundation of America Contributors: Jemima Albayda, MD; Divya Angra, MD; Alan N. Baer, MD; Sasha Bernatsky, MD, PhD; George Bertsias, MD, PhD; Ashira D. Blazer, MD; Ian Bruce, MD; Jill Buyon, MD; Yashaar Chaichian, MD; Maria Chou, MD; Sharon Christie, Esq; Angelique N. Collamer, MD; Ashté Collins, MD; Caitlin O. Cruz, MD; Mark M. Cruz, MD; Dana DiRenzo, MD; Jess D. Edison, MD; Titilola Falasinnu, PhD; Andrea Fava, MD; Cheri Frey, MD; Neda F. Gould, PhD; Nishant Gupta, MD; Sarthak Gupta, MD; Sarfaraz Hasni, MD; David Hunt, MD; Mariana J. Kaplan, MD; Alfred Kim, MD; Deborah Lyu Kim, DO; Rukmini Konatalapalli, MD; Fotios Koumpouras, MD; Vasileios C. Kyttaris, MD; Jerik Leung, MPH; Hector A. Medina, MD; Timothy Niewold, MD; Julie Nusbaum, MD; Ginette Okoye, MD; Sarah L. Patterson, MD; Ziv Paz, MD; Darryn Potosky, MD; Rachel C. Robbins, MD; Neha S. Shah, MD; Matthew A. Sherman, MD; Yevgeniy Sheyn, MD; Julia F. Simard, ScD; Jonathan Solomon, MD; Rodger Stitt, MD; George Stojan, MD; Sangeeta Sule, MD; Barbara Taylor, CPPM, CRHC; George Tsokos, MD; Ian Ward, MD; Emma Weeding, MD; Arthur Weinstein, MD; Sean A. Whelton, MD |
| car t cell therapy lupus trial: The EBMT/EHA CAR-T Cell Handbook Nicolaus Kröger, John Gribben, Christian Chabannon, Ibrahim Yakoub-Agha, Hermann Einsele, 2022-02-07 This first open access European CAR-T Handbook, co-promoted by the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), covers several aspects of CAR-T cell treatments, including the underlying biology, indications, management of side-effects, access and manufacturing issues. This book, written by leading experts in the field to enhance readers’ knowledge and practice skills, provides an unparalleled overview of the CAR-T cell technology and its application in clinical care, to enhance readers’ knowledge and practice skills. |
| car t cell therapy lupus trial: Developing Costimulatory Molecules for Immunotherapy of Diseases Manzoor Ahmad Mir, 2015-05-25 Developing Costimulatory Molecules for Immunotherapy of Diseases highlights the novel concept of reverse costimulation and how it can be effectively exploited to develop immunotherapy using either humanized antibodies against CD80, CD86, and other costimulatory molecules or CD28 fusinogenic proteins in the treatment of diseases, including allergies, asthma, rheumatoid arthritis, multiple sclerosis, lupus nephritis, severe psoriasis, vulgaris tuberculosis, thopoid, transplantation therapeutic, cancer, and inflammation. The text aims to provide the latest information on the complex roles and interactions within the CD28 and B7 costimulatory families, with the hope that targeting these families will yield new therapies for the treatment of inflammation, autoimmunity, transplantation, cancer, and other infectious diseases. - Highlights the novel concept of reverse costimulation and how it can be effectively exploited to develop immunotherapy - Provides the latest information on the complex roles and interactions within the CD28 and B7 costimulatory families - Targets new therapies for the treatment of inflammation, autoimmunity, transplantation, cancer, and other infectious diseases |
| car t cell therapy lupus trial: Cancer Immunology and Immunotherapy Mansoor M. Amiji, Lara Scheherazade Milane, 2021-08-18 Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy examines the challenges of delivering immuno-oncology therapies. Immuno-oncology (IO) is a growing field of medicine at the interface of immunology and cancer biology leading to development of novel therapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, that are clinically approved approaches for cancer therapy. Although currently approved IO approaches have shown tremendous promise for select types of cancers, broad application of IO strategies could even further improve the clinical success, especially for diseases such as pancreatic cancer, brain tumors where the success of IO so far has been limited. Nanotechnology-based targeted delivery strategies could improve the delivery efficiency of IO agents as well as provide additional avenues for novel therapeutic and vaccination strategies. Additionally, a number of locally-administered immunogenic scaffolds and therapeutic strategies, such as the use of STING agonist, could benefit from rationally designed biomaterials and delivery approaches. Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy creates a comprehensive treaty that engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side. - Comprehensive treaty covering all aspects of immuno-oncology (IO) - Novel strategies for delivery of IO therapeutics and vaccines - Forecasting on the future of nanotechnology and drug delivery for IO |
| car t cell therapy lupus trial: CD4+CD25+ Regulatory T Cells: Origin, Function and Therapeutic Potential B. Kyewski, Elisabeth Suri-Payer, 2006-01-09 The vertebrate immune system defends the organism against invading pathogens while at the same time being self-tolerant to the body’s own constituents thus preserving its integrity. Multiple mechanisms work in concert to ensure self-tolerance. Apart from purging the T cell repertoire from auto-reactive T cells via negative selection in the thymus dominant tolerance exerted by regulatory T cells plays a major role in tolerance imposition and maintenance. Among the various regulatory/suppressive cells hitherto described, CD4+CD25+ regulatory T cells (Treg) and interleukin-10 producing T regulatory 1 (Tr1) cells have been studied in most detail and are the subject of most articles in this issue. Treg, also called natural regulatory T cells, will be traced from their intra-thymic origin to the site of their action in peripheral lymphoid organs and tissues. The repertoire of Treg is clearly biased towards recognition of self-antigens, thereby potentially preventing autoimmune diseases such as gastritis and oophoritis. Regulatory T cells, however also control infections, allergies and tolerance to transplanted tissues and this requires their induction in the periphery under conditions which are not yet fully understood. The concept of dominant tolerance, by far not novel, will offer new insights and hopefully tools for the successful treatment of autoimmune diseases, improved cancer immunotherapy and transplant survival. The fulfillment of these high expectations will, however, require their unambiguous identification and a better understanding of their mode of action. |
| car t cell therapy lupus trial: Dubois' Lupus Erythematosus and Related Syndromes - E-Book Daniel J. Wallace, Bevra Hahn, 2018-08-16 For more than 50 years, Dubois' Lupus Erythematosus and Related Syndromes has been recognized internationally as the go-to clinical reference on lupus and other connective tissue diseases. From basic scientific principles to practical points of clinical management, the updated 9th Edition provides extensive, authoritative coverage of systemic lupus erythematosus (SLE) and its related diseases in a logical, clearly written, user-friendly manner. It's an ideal resource for rheumatologists and internal medicine practitioners who need a comprehensive clinical reference on all aspects of SLE, connective tissue diseases, and the antiphospholipid syndromes. - Provides complete clinical coverage of every aspect of cutaneous and systemic lupus erythematosus, including definitions, pathogenesis, autoantibodies, clinical and laboratory features, management, prognosis, and patient education. - Contains an up-to-date overview of significant advances in cellular, molecular, and genetic technologies, including genetic advancements in identifying at-risk patients. - Offers an increased focus on the clinical management of related disorders such as Sjogren's syndrome, scleroderma, polymyositis, and antiphospholipid syndrome (APS). - Presents the knowledge and expertise of more international contributors to provide new global perspectives on manifestations, diagnosis, and treatment. - Features a vibrant, full-color format, with graphs, algorithms, differential diagnosis comparisons, and more schematic diagrams throughout. |
| car t cell therapy lupus trial: Immune Regulation Marc Feldmann, N. A. Mitchison, 2012-12-06 Leukocyte culture conferences have a long pedigree. This volume records some of the scientific highlights of the 16th such annual con ference, and is a witness to the continuing evolution and popularity of leukocyte culture and of immunology. There is strong evidence of the widening horizons of immunology, both technically, with the obviously major impact of molecular biology into our understanding of cellular processes, and also conceptually. Traditionally, the 'proceedings' of these conferences have been published. But have the books produced really recorded the major part of the conference, the informal, friendly, but intense and some times heated exchanges that take place between workers in tackling very similar problems and systems and which are at the heart of every successful conference? Unfortunately this essence cannot be incorpo rated by soliciting manuscripts. For this reason, we have changed the format of publication, retaining published versions of the symposium papers, but requesting the workshop chairmen to produce a summary of the major new observations and areas of controversy highlighted in their sessions, as a vehicle for defining current areas of interest and debate. Not an easy task, as the workshop topics were culled from the abstracts submitted by the participants, rather than being on predefined topics. The unseasonal warmth in Cambridge was reflected in the atmos phere of the conference, the organization of which benefited from the administrative skills of Jean Bacon, Philippa Wells, Mr. Peter Irving, and Mrs. |
| car t cell therapy lupus trial: A Clinician's Pearls & Myths in Rheumatology John H. Stone, 2009-10-03 Important strides have been made in understanding the pathophysiologic basis of many inflammatory conditions in recent years, but rheumatology remains a discipline in which diagnosis is rooted in the medical history skillfully extracted from the patient, the careful physical examination, and the discriminating use of laboratory tests and imaging. Moreover, selection of the most appropriate therapy for patients with rheumatic diseases also remains heavily reliant upon clinical experience. Medical disciplines such as rheumatology that depend significantly upon clinical wisdom are prone to the development of systems of ‘Pearls’ and ‘Myths,’ related to the diseases they call their own, a ‘Pearl’ being a nugget of truth about the diagnosis or treatment of a particular disease that has been gained by dint of clinical experience and a ‘Myth’ being a commonly held belief that influences the practice of many clinicians – but is false. This book will pool together the clinical wisdom of seasoned, expert rheumatologists who participate in the care of patients with autoimmune diseases, systemic inflammatory disorders, and all other rheumatic conditions. |
| car t cell therapy lupus trial: Mesenchymal Stem Cell Therapy Lucas G. Chase, Mohan C Vemuri, 2012-12-12 Over the past decade, significant efforts have been made to develop stem cell-based therapies for difficult to treat diseases. Multipotent mesenchymal stromal cells, also referred to as mesenchymal stem cells (MSCs), appear to hold great promise in regards to a regenerative cell-based therapy for the treatment of these diseases. Currently, more than 200 clinical trials are underway worldwide exploring the use of MSCs for the treatment of a wide range of disorders including bone, cartilage and tendon damage, myocardial infarction, graft-versus-host disease, Crohn’s disease, diabetes, multiple sclerosis, critical limb ischemia and many others. MSCs were first identified by Friendenstein and colleagues as an adherent stromal cell population within the bone marrow with the ability to form clonogenic colonies in vitro. In regards to the basic biology associated with MSCs, there has been tremendous progress towards understanding this cell population’s phenotype and function from a range of tissue sources. Despite enormous progress and an overall increased understanding of MSCs at the molecular and cellular level, several critical questions remain to be answered in regards to the use of these cells in therapeutic applications. Clinically, both autologous and allogenic approaches for the transplantation of MSCs are being explored. Several of the processing steps needed for the clinical application of MSCs, including isolation from various tissues, scalable in vitro expansion, cell banking, dose preparation, quality control parameters, delivery methods and numerous others are being extensively studied. Despite a significant number of ongoing clinical trials, none of the current therapeutic approaches have, at this point, become a standard of care treatment. Although exceptionally promising, the clinical translation of MSC-based therapies is still a work in progress. The extensive number of ongoing clinical trials is expected to provide a clearer path forward for the realization and implementation of MSCs in regenerative medicine. Towards this end, reviews of current clinical trial results and discussions of relevant topics association with the clinical application of MSCs are compiled in this book from some of the leading researchers in this exciting and rapidly advancing field. Although not absolutely all-inclusive, we hope the chapters within this book can promote and enable a better understanding of the translation of MSCs from bench-to-bedside and inspire researchers to further explore this promising and quickly evolving field. |
| car t cell therapy lupus trial: Basics of Chimeric Antigen Receptor (CAR) Immunotherapy Mumtaz Y. Balkhi, 2019-07-31 Basics of Chimeric Antigen Receptor (CAR) Immunotherapy presents the latest on how T cell adoptive immunotherapy has progressed in its ultimate goal of curing metastatic malignant cancers. Recent clinical data obtained with checkpoint receptor blockade inhibitors and chimeric antigen receptor (CAR) therapy has been especially promising, thus generating renewed hope that we may be on the verge of finally curing cancer. Over the years, huge progress has been made in controlling several stage IV metastasized cancers through the clinical application of checkpoint receptor inhibitory drugs and CAR-Therapy that has seen unprecedented interest in the immunotherapy field. - Presents the first book to provide a basic understanding of chimeric antigen receptor (CARs) design, production and clinical application protocols - Provides unique authority as the editor has worked directly with CARs - Discusses the challenges encountered in actual clinical trials and how these challenges can be overcome - Includes a full chapter on various challenges researchers should expect to encounter in the CAR-therapy field |
| car t cell therapy lupus trial: Paediatric Rheumatology Helen E. Foster, Paul A. Brogan, 2012-06-14 Paediatric Rheumatology is an indispensible resource for the identification and management of specific rheumatological disorders. As well as covering common and rare rheumatological problems, there are also chapters on investigations and emergencies, designed for quick reference. The handbook includes dedicated topics on systemic diseases affecting rheumatology; the relevant clinical guidelines and information needed for a rheumatologist to successfully management a young patient; and, a coloured section for guidance on rash-related investigations. Paediatric Rheumatology is also fully endorsed by the British Society for Paediatric and Adolescent Rheumatology and the UK Paediatric Rheumatology Clinical Studies Group. |
| car t cell therapy lupus trial: Verbal Perseveration Jacqueline Ann Stark, 2007 Introductory textbooks on neurogenic communication disorders associated with aphasia and brain injury do not provide full documentation of the pervasive influence of perseveration in the diagnosis and treatment of clients with severe language processing deficits. This special issue of Aphasiology aims to revives the profound interest in verbal perseveration observed in the classical German literature between 1890 and 1931. Various aspects of the phenomenon of perseveration are addressed in this issue. When and under what circumstances do perseverations occur? What are the characteristics of perseverative errors and how do they relate to non-perseverative sound and word errors? The papers share a common goal, namely to understand the origin of the phenomenon 'perseveration' in healthy subjects and clients with brain damage and injury. An overarching claim throughout the papers is that perseveration reflects the client's primary language processing deficits. |
| car t cell therapy lupus trial: The Lupus Book Daniel J. Wallace, 2013 Lupus, a disease of the immune system, can be quite deadly, claiming the lives of thousands of patients yearly. Dr. Daniel J. Wallace is one of the world's leading authorities on this disorder, an eminent clinician who has treated over 3000 lupus patients, the largest such practice in America. His The Lupus Book, originally published in 1995, immediately established itself as the most readable and helpful book on the disease. Now Dr. Wallace has once again completely revised The Lupus Book, incorporating a wealth of new information. This Fifth Edition discusses new drug information and newly discovered information about the pathology of the disease--all laid out in user-friendly language that any patient could understand. In particular, Wallace discusses the first drug for Lupus to be approved by the FDA--belimumab (Benlysta)--as well as other drugs in clinical trials. Readers will also discover fully updated sections on the science of lupus and breakthroughs in research. And as in past editions, the book provides absolutely lucid answers to such questions as: What causes lupus? How and where is the body affected? Can a woman with lupus have a baby? And how can one manage this disease? Indeed, Dr. Wallace has distilled his extensive experience, providing the most up-to-date information on causes, prevention, cure, exercise, diet, and many other important topics. There is also a glossary of terms and an appendix of lupus resource materials compiled by the Lupus Foundation of America. Over a million Americans have lupus. The new Fifth Edition offers these patients and their families an abundance of reliable, up-to-date information that will help them manage the disease and live a happier life. |
| car t cell therapy lupus trial: Biological Collections National Academies of Sciences, Engineering, and Medicine, Division on Earth and Life Studies, Board on Life Sciences, Committee on Biological Collections: Their Past, Present, and Future Contributions and Options for Sustaining Them, 2021-01-29 Biological collections are a critical part of the nation's science and innovation infrastructure and a fundamental resource for understanding the natural world. Biological collections underpin basic science discoveries as well as deepen our understanding of many challenges such as global change, biodiversity loss, sustainable food production, ecosystem conservation, and improving human health and security. They are important resources for education, both in formal training for the science and technology workforce, and in informal learning through schools, citizen science programs, and adult learning. However, the sustainability of biological collections is under threat. Without enhanced strategic leadership and investments in their infrastructure and growth many biological collections could be lost. Biological Collections: Ensuring Critical Research and Education for the 21st Century recommends approaches for biological collections to develop long-term financial sustainability, advance digitization, recruit and support a diverse workforce, and upgrade and maintain a robust physical infrastructure in order to continue serving science and society. The aim of the report is to stimulate a national discussion regarding the goals and strategies needed to ensure that U.S. biological collections not only thrive but continue to grow throughout the 21st century and beyond. |
| car t cell therapy lupus trial: Rapid Test Laura Anfossi, 2018-09-26 Rapid tests, also known as point-of-care tests, have been in use for decades in the clinical and medical area and have become increasingly popular as an efficient screening method for conducting on-site analysis thanks to their simplicity, speed, specificity and sensitivity. Nowadays, rapid tests are widely applied for clinical, drug, food, forensic and environmental analysis and fields of application are rapidly increasing together with advances in the technology. The growing interest in rapid tests and their expanding application in diverse fields, together with requirements of improved sensitivity, reliability, multiple detection capacity and robustness, are prompting innovation in the design of novel platforms, and in the exploitation of innovative detection strategies. The book covers advances in materials, technology and test design. |
| car t cell therapy lupus trial: The EBMT Handbook Nicolaus Kröger, Mohamad Mohty, Carlo Dufour, 2020-10-08 This Open Access edition of the European Society for Blood and Marrow Transplantation (EBMT) handbook addresses the latest developments and innovations in hematopoietic stem cell transplantation and cellular therapy. Consisting of 93 chapters, it has been written by 175 leading experts in the field. Discussing all types of stem cell and bone marrow transplantation, including haplo-identical stem cell and cord blood transplantation, it also covers the indications for transplantation, the management of early and late complications as well as the new and rapidly evolving field of cellular therapies. This book provides an unparalleled description of current practices to enhance readers' knowledge and practice skills. This work was published by Saint Philip Street Press pursuant to a Creative Commons license permitting commercial use. All rights not granted by the work's license are retained by the author or authors. |
| car t cell therapy lupus trial: Mosaic of Autoimmunity Carlo Perricone, Yehuda Shoenfeld, 2019-02-13 The Mosaic of Autoimmunity: The Novel Factors of Autoimmune Diseases describes the multifactorial origin and diversity of expression of autoimmune diseases in humans. The term implies that different combinations of factors in autoimmunity produce varying and unique clinical pictures in a wide spectrum of autoimmune diseases. Most of the factors involved in autoimmunity can be categorized into four groups: genetic, immune defects, hormonal and environmental factors. In this book, the environmental factors are reviewed, including infectious agents, vaccines as triggers of autoimmunity, smoking and its relationship with rheumatoid arthritis, systemic lupus erythematosus, thyroid disease, multiple sclerosis and inflammatory bowel diseases. An entirely new syndrome, the autoimmune/inflammatory syndrome induced by adjuvants (ASIA), is also included, along with other diseases that are now recognized as having an autoimmune etiopathogenesis. |
| car t cell therapy lupus trial: Moderate to Severe Psoriasis John Koo, Jashin Wu, Alice Gottlieb, Ethan Levin, Argentina Leon, 2014-03-18 Written by experts in the dermatology field, this new fourth edition of Moderate-to-Severe Psoriasis discusses the current use of biologics and other pharmacologic and phototherapy treatments for moderate-to-severe psoriasis. Illustrated with high quality color figures, this standalone text emphasizes safe and effective treatments for the psoriasis |
| car t cell therapy lupus trial: Principles and Practice of Pediatric Oncology Philip A. Pizzo, 2011 Thoroughly updated for its Sixth Edition,Principles and Practice of Pediatric Oncologyprovides a comprehensive review of the multiple disciplines that make up the care and research agendas for children with cancer. It is the most comprehensive textbook of pediatric oncology ever put together, covering biology and genetics and detailing the diagnosis, multimodal treatment, and long-term management of patients with cancer. The fundamental principles of supportive care and the psychosocial aspects of support for patients and families are also discussed. |
| car t cell therapy lupus trial: SITC’s Guide to Managing Immunotherapy Toxicity Marc S. Ernstoff, MD, Igor Puzanov, MD, MSCI, FACP, Caroline Robert, MD, PhD, Adi M. Diab, MD, Peter M. Hersey, MD, PhD, 2019-03-15 The Society for Immunotherapy of Cancer's handbook,SITC’s Guide to Managing Immunotherapy Toxicity, is a practical reference to managing side effects associated with FDA-approved cancer immunotherapy drugs. Separated into two parts, Part I contains chapter-based overviews of immune checkpoint inhibitors in the clinic, starting with anti-CTLA4 agents, anti-PD1/PD-L1 agents, and approved immunotherapeutic combinations. These chapters cover relevant mechanisms of action, indications, and toxicities seen while combating early, advanced, and metastatic stages in cancer patients. Part II is structured by common and uncommon toxicities that affect major organ sites throughout the body. It begins with a general summary of principles and management options followed by chapters focusing on specific toxicities such as rash and mucosal irritation, muscle and joint toxicity, diarrhea and colitis, pneumonitis, endocrine toxicities, neurological toxicities, cardiac toxicity, renal toxicity, hematologic toxicity, and ocular toxicities. Each chapter provides guidance on how to assess and treat the toxicity and how to support the patient through acute and chronic effects with detailed summary tables for quick reference. Part II concludes with chapters covering management of special patient populations, including patients with autoimmune disease and geriatric patients, treatment and management of fatigue, and a final chapter dedicated to cost effectiveness and the toll of financial toxicity on patients and caregivers. With chapters written by world-recognized leaders in the immuno-oncology field, this text provides thorough coverage of the toxicity and management of adverse effects for immune checkpoint inhibitors. It is an indispensable resource for clinical oncologists, emergency physicians, hospitalists and other medical practitioners in both the hospital and community clinic settings, especially as the use of immune checkpoint inhibitors becomes a fixture in oncology care. Key Features: Outlines strategies for treating high-risk patients facing an acute or chronic side effect to immunotherapy Provides numerous tables that condense and highlight pertinent information for quick reference Describes the various clinical presentations and toxic reactions caused by immunotherapy Purchase includes access to the eBook for use on most mobile devices or computer |
| car t cell therapy lupus trial: Breakthrough in Immunotherapy Baptiste Durand, Anders Olofson, Thomas Clark, 2024-08-22 |
| car t cell therapy lupus trial: IgG4-Related Sclerosing Cholangitis Terumi Kamisawa, Myung-Hwan Kim, 2018-07-31 This book aims to raise awareness of IgG4-related sclerosing cholangitis among practicing physicians and to equip readers with a sound understanding of the principles of diagnosis and treatment. Clinical, serological, and histopathological features are clearly described and imaging appearances on all relevant modalities are illustrated, covering the bile duct and other involved organs. Differential diagnosis from other diseases, including primary sclerosing cholangitis and cholangiocarcinoma, is precisely explained. Information is then presented on all significant current and emerging therapeutic strategies, including steroids, immunosuppressive drugs, and rituximab. Finally, attention is drawn to significant prognostic features. While IgG4-related sclerosing cholangitis is now a widely acknowledged condition, most practitioners are still liable to misdiagnose it owing to a lack of familiarity with its presenting features. This book should help to rectify the situation and will be an asset for all who may encounter the disease in clinical practice. |
| car t cell therapy lupus trial: How Tobacco Smoke Causes Disease United States. Public Health Service. Office of the Surgeon General, 2010 This report considers the biological and behavioral mechanisms that may underlie the pathogenicity of tobacco smoke. Many Surgeon General's reports have considered research findings on mechanisms in assessing the biological plausibility of associations observed in epidemiologic studies. Mechanisms of disease are important because they may provide plausibility, which is one of the guideline criteria for assessing evidence on causation. This report specifically reviews the evidence on the potential mechanisms by which smoking causes diseases and considers whether a mechanism is likely to be operative in the production of human disease by tobacco smoke. This evidence is relevant to understanding how smoking causes disease, to identifying those who may be particularly susceptible, and to assessing the potential risks of tobacco products. |
| car t cell therapy lupus trial: Cytokine Storm Syndrome Randy Q. Cron, |
| car t cell therapy lupus trial: Immune Checkpoint Inhibitors in Cancer Fumito Ito, Marc Ernstoff, 2018-09-03 Get a quick, expert overview of the latest clinical information and guidelines for cancer checkpoint inhibitors and their implications for specific types of cancers. This practical title by Drs. Fumito Ito and Marc Ernstoff synthesizes the most up-to-date research and clinical guidance available on immune checkpoint inhibitors and presents this information in a compact, easy-to-digest resource. It's an ideal concise reference for trainee and practicing medical oncologists, as well as those in research. - Discusses the current understanding of how to best harness the immune system against different types of cancer at various stages. - Helps you translate current research and literature into practical information for daily practice. - Presents information logically organized by disease site. - Covers tumor immunology and biology; toxicities associated with immune checkpoint inhibitors; and future outlooks. - Consolidates today's available information on this timely topic into one convenient resource. |
| car t cell therapy lupus trial: The Role of NIH in Drug Development Innovation and Its Impact on Patient Access National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Board on Health Care Services, 2020-01-27 To explore the role of the National Institutes of Health (NIH) in innovative drug development and its impact on patient access, the Board on Health Care Services and the Board on Health Sciences Policy of the National Academies jointly hosted a public workshop on July 24â€25, 2019, in Washington, DC. Workshop speakers and participants discussed the ways in which federal investments in biomedical research are translated into innovative therapies and considered approaches to ensure that the public has affordable access to the resulting new drugs. This publication summarizes the presentations and discussions from the workshop. |
| car t cell therapy lupus trial: Lahita's Systemic Lupus Erythematosus Robert G. Lahita, 2021-07-27 Systemic lupus erythematosus (SLE), commonly called lupus, is a chronic autoimmune disorder that can affect virtually any organ of the body. In lupus, the body's immune system, which normally functions to protect against foreign invaders, becomes hyperactive, forming antibodies that attack normal tissues and organs, including the skin, joints, kidneys, brain, heart, lungs, and blood. Lupus is characterized by periods of illness, called flares, and periods of wellness or remission. Because its symptoms come and go and mimic those of other diseases, lupus is difficult to diagnose. There is no single laboratory test that can definitively prove that a person has the complex illness. To date, lupus has no known cause or cure. Early detection and treatment are the key to a better health outcome and can usually lessen the progression and severity of the disease. Anti-inflammatory drugs, antimalarials, and steroids (such as cortisone and others) are often used to treat lupus. Cytotoxic chemotherapies, like those used in the treatment of cancer, are also used to suppress the immune system in lupus patients. A new edition of this established and well-regarded reference combines basic science with clinical science to provide a translational medicine model. Systemic Lupus Erythematosus, Sixth Edition, is a useful reference for specialists in the diagnosis and management of patients with SLE, a tool for measurement of clinical activity for pharmaceutical development and basic research of the disease, and a reference work for hospital libraries. Completely updated, revised, and expanded with the most comprehensive and accessible reference on SLE for clinicians and scientists Full-color presentation throughout the book Provides the latest information available on diagnosis and treatment Incorporates an international panel of authors who are experts in their fields, with an emphasis on young, cutting-edge scientists and physicians |
| car t cell therapy lupus trial: Advance in B-cell therapies for the treatment of rheumatic and musculoskeletal diseases Md Yuzaiful Md Yusof, Stefano Alivernini, Katerina Chatzidionysiou, 2023-05-03 |
| car t cell therapy lupus trial: Encountering Pain Deborah Padfield, Joanna M. Zakrzewska, 2021-02-15 What is persistent pain? How do we communicate pain, not only in words but in visual images and gesture? How do we respond to the pain of another, and can we do it better? Can explaining how pain works help us handle it? This unique compilation of voices addresses these and bigger questions. Defined as having lasted over three months, persistent pain changes the brain and nervous system so pain no longer warns of danger: it seems to be a fault in the system. It is a major cause of disability globally, but it remains difficult to communicate, a problem both to those with pain and those who try to help. Language struggles to bridge the gap, and it raises ethical challenges in its management unlike those of other common conditions. Encountering Pain shares leading research into the potential value of visual images and non-verbal forms of communication as means of improving clinician–patient interaction. It is divided into four sections: hearing, seeing, speaking, and a final series of contributions on the future for persistent pain. The chapters are accompanied by vivid photographs co-created with those who live with pain. The volume integrates the voices of leading scientists, academics and contemporary artists with poetry and poignant personal testimonies to provide a manual for understanding the meanings of pain, for healthcare professionals, pain patients, students, academics and artists. The voices and experiences of those living with pain are central, providing tools for discussion and future research, shifting register between creative, academic and personal contributions from diverse cultures and weaving them together to offer new understanding, knowledge and hope. |
| car t cell therapy lupus trial: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues World Health Organization, 2001 This is the third volume in the new World Health Organization series on histological and genetic typing of tumours. Tumours of the haematopoietic and lymphoid tissues are covered. This was a collaborative project of the European Association for Haematolpathology and the Society for Haematopathology and others. The WHO classification is based on the principles defined in the Revised European-American Classification of Lymphoid Neoplasms (REAL) classification. Over 50 pathologists from around the world were involved in the project and proponents of all major lymphoma and leukaemia classifications have agreed to accept the WHO as the standard classification of haematological malignancies. So this classification represents the first true world wide concensus of haematologic malignancies. Colour photographs, magnetic resonance and ultrasound images and CT scans are included. |
| car t cell therapy lupus trial: Lupus, An Issue of Rheumatic Disease Clinics of North America, E-Book Zahi Touma, Alfred Kim, 2021-07-06 This issue of Rheumatic Disease Clinics, guest edited by Dr. Alfred Kim and Zahi Touma, will discuss a number of key topics surrounding Lupus. This issue is one of four selected each year by series Consulting Editor, Dr. Michael Weisman. Topics discussed in this issue include, but are not limited to: Interferons in SLE, NETosis and neutrophils in SLE, AMP update in lupus nephritis, Patient-reported outcomes, Complement, T cells in SLE, B cells in SLE, Outcome measures for SLE clinical trials, Mitochondrial physiology in SLE, Pregnancy, Lupus cohorts, Innovative trials and new opportunities in SLE, Classification and diagnosis of SLE, and Updates on SLE Treatment. |
| car t cell therapy lupus trial: Dubois' Lupus Erythematosus and Related Syndromes - E-Book Daniel J. Wallace, Bevra Hahn, 2023-12-04 For more than 50 years, Dubois' Lupus Erythematosus and Related Syndromes has been recognized internationally as the go-to clinical reference on lupus and other connective tissue diseases. From basic scientific principles to practical points of clinical management, the 10th edition provides extensive, authoritative coverage of systemic lupus erythematosus (SLE) and its related diseases in a logical, clearly written, user-friendly manner. It's an ideal resource for rheumatologists and internal medicine practitioners who need a comprehensive clinical reference on all aspects of SLE, connective tissue diseases, and the antiphospholipid syndromes. - Provides complete clinical coverage of every aspect of cutaneous and systemic lupus erythematosus, including definitions, pathogenesis, autoantibodies, clinical and laboratory features, management, prognosis, and patient education. - Includes significant new content throughout: a new chapter on the endocrine system and hormones; newly distinct chapters on the heart and lung; new content on social disparities in lupus, clinical presentation of nephritis, and pulmonary hypertension; a new concluding chapter on future directions in the field; new basic science coverage of the microbiome, autoinflammatory, and monogenic lupus; and new coverage of diversity, inclusion, gender, compliance, and adherence. - Offers a fresh perspective from two new associate editors and many new authors with representation from 30 countries. - Contains an up-to-date overview of significant advances in cellular, molecular, and genetic technologies, including genetic advancements in identifying at-risk patients. - Discusses the clinical management of related disorders such as Sjogren's syndrome, scleroderma, polymyositis, and antiphospholipid syndrome (APS). - Presents the knowledge and expertise of international contributors to provide new global perspectives on manifestations, diagnosis, and treatment. - Features a vibrant, full-color format, with graphs, algorithms, differential diagnosis comparisons, new and improved figures, and schematic diagrams throughout. - Additional digital ancillary content may publish up to 6 weeks following the publication date. |
| car t cell therapy lupus trial: Paediatric Nephrology Lesley Rees, Detlef Bockenhauer, Nicholas J.A. Webb, 2012-06-28 This pocket-sized book is designed to provide up-to-date information for the general paediatrican and paediatric nephrologist, including advice on care of emergencies, chronic disorders and covering common and rare conditions. It is highly relevant for the day-to-day care of patients on the ward or in the outpatient clinic. |
| car t cell therapy lupus trial: Hospitalist Neurology Martin A. Samuels, 1999 Hospitalist Neurology, in the highly regarded Blue Books of Practical Neurology series, focuses on the clinical practice of in-patient neurology as well as the neurologic sequelae of non-neurologic conditions of hospitalized patients. It is meant to provide consulting hospital-based neurologists with a rational approach to evaluating neurological problems in a busy general hospital. |
| car t cell therapy lupus trial: Cell and Gene Therapies Miguel-Angel Perales, Syed A. Abutalib, Catherine Bollard, 2018-11-27 In this book, experts in the field express their well-reasoned opinions on a range of complex, clinically relevant issues across the full spectrum of cell and gene therapies with the aim of providing trainee and practicing hematologists, including hematopoietic transplant physicians, with information that is relevant to clinical practice and ongoing research. Each chapter focuses on a particular topic, and the concise text is supported by numerous working tables, algorithms, and figures. Whenever appropriate, guidance is provided regarding the availability of potentially high-impact clinical trials. The rapid evolution of cell and gene therapies is giving rise to numerous controversies that need to be carefully addressed. In meeting this challenge, this book will appeal to all residents, fellows, and faculty members responsible for the care of hematopoietic cell transplant patients. It will also offer a robust, engaging tool to aid vital activities in the daily work of every hematology and oncology trainee. |
| car t cell therapy lupus trial: Stem Cell Therapy: A Rising Tide: How Stem Cells Are Disrupting Medicine and Transforming Lives Neil H. Riordan, 2017-06-20 Stem cells are the repair cells of your body. When there aren't enough of them, or they aren't working properly, chronic diseases can manifest and persist. From industry leaders, sport stars, and Hollywood icons to thousands of everyday, ordinary people, stem cell therapy has helped when standard medicine failed. Many of them had lost hope. These are their stories. Neil H Riordan, author of MSC: Clinical Evidence Leading Medicine's Next Frontier, the definitive textbook on clinical stem cell therapy, brings you an easy-to-read book about how and why stem cells work, and why they're the wave of the future. |
| car t cell therapy lupus trial: New Targeting in The Reversal of Resistant Glioblastomas Ali Syed Arbab, 2021-03-10 New Targeting in The Reversal of Resistant Glioblastomas discusses alternative treatment strategies that not only target tumor cells but also target the tumor microenvironment, metabolic pathways and interaction of cytokines in tumor cells. The current treatment for primary and recurrent glioblastomas is failing because clinicians are not considering the effect of bone marrow derived cells to the development of resistance to clinically practiced therapies. This book helps readers rethink treatment strategies to successfully fight glioblastomas. It is a valuable resource for cancer researchers, clinicians, graduate students and other members of the biomedical field. Explains the effect of bone marrow derived cells on the development of resistance to clinically practiced therapies Provides information on the availability of alternate therapies for recurrent glioblastoma when standard practices have failed Discusses targeting tumor microenvironment using available FDA approved drugs as an alternative treatment strategy for glioblastoma |
| car t cell therapy lupus trial: Fighting Health Insurance Denials Scott Glovsky, 2016-01-15 Health insurance companies claim to act in their customers' best interests, but quite often fail to deliver on that promise. In this step-by-step guide, health insurance attorney Scott Glovsky examines the lawyer's role in helping a client navigate a health insurance denial, from understanding consumer rights, the appeals process, independent medical review, through the intricacies of an insurance bad faith lawsuit, and how the Affordable Care Act has impacted health care law. Drawing from decades of experience from large firms and from his own private practice, Scott uses his unique client-centered approach to shed light on this important and often misunderstood practice area. |
r/Cars - For Car Enthusiasts - Reddit
r/Cars is the largest automotive enthusiast community on the Internet. We're Reddit's central hub for vehicle-related discussion, industry news, reviews, projects, DIY guides, advice, stories, …
Former CarMax employee here. If you plan to go in for an ... - Reddit
Feb 3, 2021 · Where younger an estimated value and when you come in our car buyer puts in his notes and we show you side by side. Where you thought you were and didn't mention that …
How much do car salesmen REALLY make? : r/askcarsales - Reddit
Apr 26, 2022 · Is 6 figures in car sales the norm? EDIT: 25M, single, no kids. Currently in civil engineering with $78k salary in LCOL area (central texas). Seems like folks are making well …
Hoseheadforums.com Home
Aug 17, 2013 · Bodnar Motorsports building new car for 2019 viewed (10751) Wicked Energy Gum to Sponsor the Northwest Focus Midget Series viewed (8765) Heartland Motorsports …
best places to search for used cars : r/cars - Reddit
Sep 7, 2018 · r/Cars is the largest automotive enthusiast community on the Internet. We're Reddit's central hub for vehicle-related discussion, industry news, reviews, projects, DIY …
Car dealership scratch-off mailer scam (Update) : r/Scams - Reddit
Mar 12, 2019 · I posted a couple of days ago about a scratch-off contest mailer that I had received from a local car dealership. My "game piece" seemed to indicate that I had won the Grand …
Nothing Under - Reddit
r/NothingUnder: Dresses and clothing with nothing underneath. Women in outfits perfect for flashing, easy access, and teasing men.
What’s the best auto insurance? : r/Insurance - Reddit
I also know that being young and driving a newer car is the reason behind all this, but any advice/tips about all this is much needed! Is the monthly rate really normal for someone my …
HoseHeads Sprint Car General Forum - Oval Track Racing Forums
4 days ago · Forum: HoseHeads Sprint Car General Forum Moderators: dirtonly / dmantx / hosehead First
I've been scouring the internet for a working download link to
Aug 26, 2023 · 31 votes, 30 comments. 36K subscribers in the E90 community. Hub for all BMW 3 series, 2006-2013. Anyone is welcome!
Gracell Biotechnologies Initiates Investigational Study …
Gracell announces start of investigator-initiated trial to expand clinical evaluation of FasTCAR-T GC012F into autoimmune disease ... Systemic lupus erythematosus (SLE) is a chronic …
From concept to reality: CAR‐T therapy as a glimmer of hope …
TULIP trial and the BLISS- LN trials achieved success in SLE during recent years and brought SLE into the biological era with anifrolumab ... CAR- T- cell therapy has played a vital role in …
CAR T-cell therapy rescues adolescent with rapidly …
strongly suggests a causal effect of CAR T-cell treatment. Notably, the patient returned to school at month 4 after CAR T-cell therapy initiation and, at time of publication, is fully active in her …
First in Human Data of NKX019, an Allogeneic CAR NK for the …
NK-cell therapy may address challenges associated with CAR-T therapy. Methods This is an open label, phase 1 trial (NCT05020678) for adults with r/r B-cell malignancies with ≥2 prior lines of …
Cytokine and reactivity profiles in SLE patients following anti …
anti-CD19 CAR T cell therapy induces sustained drug-free remis-sion in SLE patients.8 To further our understanding of the potential correlates of remission, we performed high-dimensional …
CAR-Ts sweep into autoimmunity - Nature
BCMA-CD19 compound CAR iCell Gene Therapeutics Chimeric BCMA CD19 SLE, lupus nephritis 1 recruiting CABA-201 Cabaletta Bio CD19 SLE, idiopathic inflammatory myopathy
CAR T-Cell Therapy: A Promising Modality for Autoimmune …
rheumatoid arthritis or systemic lupus erythematosus. CAR Tregs: Another promising approach is to generate antigen-specific regulatory T-cells (Tregs) against ... FDA approved the first …
Local immune effector cell-associated toxicity syndrome in …
severe autoimmune diseases such as systemic lupus erythematosus (SLE), systemic sclerosis, and idiopathic ... In the context of CAR T-cell therapy of autoimmune . disease in our centres, …
A Phase 1 Study of NKX019, a CD19 Chimeric Antigen …
autologous CAR T cell therapy for B-cell malignancies • Over 500,000 people are diagnosed with B cell-derived cancers each year, including non-Hodgkin lymphoma (NHL) and acute …
PHASE I TRIAL OF MB-CART2019.1 IN PATIENTS WITH …
benefit from currently approved CAR T cell therapies, indicating a significant unmet medical need for further improvements1–3 • Relapses after CD19-directed CAR T cell therapy occur in …
Determinants of resistance to engineered T cell therapies …
Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas Graphical abstract Highlights d Tumors and CAR T cell effectors can be …
AbelZeta Announces Upcoming Oral Presentations at LUPUS …
Lupus Erythematosus (“LUPUS 2025”), to be held in Toronto, Canada on May 21-24, 2025. C-CAR168 is a novel autologous bi-specific CAR-T therapy targeting both CD20 and B-cell …
CAR-T cell therapy in rheumatic diseases: a review article
graphics, CAR-T targets, treatment outcomes, and safety proles. It evaluated the clinical trial designs, endpoint selection, and statistical power and highlighted the ndings and limitations of …
CAR-T cell therapy clinical trials: global progress, challenges, …
May 20, 2025 · CAR-T cell therapy clinical trials: global progress, challenges, and future directions from ClinicalTrials.gov insights Li-Ya Cao1, Yue Zhao1, Yang Chen2, Pan Ma1, Jiang-Chuan …
| IN HUMAN DATA OF NKX019, AN ALLOGENEIC CAR NK FOR …
Oct 6, 2023 · First in Human Data of NKX019, an Allogeneic CAR NK for the Treatment of Relapsed/refractory (r/r) B-cell Malignancies Michael Dickinson1, Nada Hamad2, Christian …
CD19-directed T cell–engaging antibodies for the treatment …
Given the recent CAR-T cell therapy data, CD19 is emerging as the B cell target with the highest potential to achieve durable ... studies with CD19-directed CAR-T cell therapies in severe …
Preliminary efficacy and safety of Relmacabtagene autoleucel …
The recent development of chimeric antigen receptor (CAR)-T cell therapy has provided a novel and effective treatment strategy for patients with relapsed/refractory (r/r) FL.1,2 …
THE CAR T-CELL THERAPY CLINICAL TRIAL JOURNEY
6 side effects typical car t-cell therapy side effects 50 why do side effects occur? 51 signs and symptoms to watch for 53 support along the journey introduction 56 enhanced supportive care …
A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy …
%PDF-1.6 %âãÏÓ 1 0 obj > endobj 2 0 obj > endobj 3 0 obj > endobj 5 0 obj > endobj 6 0 obj >/Font >/ProcSet[/PDF/Text]/ExtGState >>> endobj 7 0 obj > endobj 8 0 ...
Abstracts - Lupus Science & Medicine
Lupus Science & Medicine: first published as 10.1136/lupus-2024-el.222 on 14 March 2024. Downloaded from https://lupus.bmj.com on 9 June 2025 by guest. Protected by copyright, …
Interim analysis of a Phase II study …
leftborder borderright border top for pictures and shapes for text border top bottom border for Photos and •CD19 CAR T cell therapy is an established treatment for pts with R/R DLBCL …
Reference list CliniMACS Prodigy® T Cell Transduction
Reference list CliniMACS Prodigy® T Cell Transduction Shah, N. N. et al. (2020) Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: A phase 1 dose escalation and …
Beyond the blood: expanding CAR T cell therapy to solid …
approaches, CAR T cell therapy stands out for its considerable efficacy, particularly in treating certain hematological malignancies using CD19- and B cell maturation antigen (BCMA) …
From concept to reality: CAR‐T therapy as a glimmer of hope …
TULIP trial and the BLISS- LN trials achieved success in SLE during recent years and brought SLE into the biological era with anifrolumab ... CAR- T- cell therapy has played a vital role in …
Allogeneic anti-CD19 CAR-T cells induce remission in
Following the first clinical use of autologous CAR-T cell therapy in a patient with relapsed/refractory systemic lupus erythematosus (SLE), numerous clinical trials have been …
Frontiers in CAR-T cell therapy for autoimmune diseases
May 30, 2024 · Frontiers in CAR-T cell therapy for autoimmune diseases Yan-Ruide Li 1,5,*, Zibai Lyu1,5, Yuning Chen ... (MS), systemic lupus erythematosus (SLE), type 1 diabetes mellitus …
The enchanting canvas of CAR technology: Unveiling its
research findings and clinical trial advancements into practical therapies for a range of medical conditions, beyond just cancer, and are investigating the potential use of ... Non-specific B …
Chimeric antigen receptor T cell therapy for autoimmune …
CAR T cell therapy for the treatment of autoimmune diseases. Sections Introduction ... trial in lupus nephritis 56. In addition to the depth of depletion, the breadth of depletion
Lupus Nephritis Management Guidelines - medicine.musc.edu
trial but would be interested & willing LFA. RAY: Research Accelerated by You. Annual Report 2023 CAR-T Cell Therapy • Synthetic chimeric antigen receptors (CAR) T cells engineered to …
Preclinical Evaluation of ALLO‑329: Allogeneic CD19 CAR T …
T cells. A CD19/CD70 dual CAR T cell therapy may therefore reduce or eliminate the need for lymphodepleting conditioning regimens that are typically required prior to CAR T cell infusion. …
News in brief NKs for lupus poised for trial - Nature
NKs for lupus poised for trial N ... (CAR) natural killer cell (NK) therapy in autoimmune lupus nephritis after receiv-ing approval from the US Food and Drug Administration (FDA) to test …
A phase I open-label single-arm study of dual targeting …
Designed to address major challenges faced by conventional autologous CAR-T Key advantages: • Faster to patient • Enhanced CAR-T cell quality and materially higher concentration of young …
Bristol Myers Squibb Highlights Advancing Pipeline and …
• CD19-directed NEX T cell therapy BMS-986353, expanding into clinical trials for immunologic diseases, including severe, refractory systemic lupus erythematosus. • Potential first cell …
Lipid nanoparticles outperform electroporation in mRNA …
and controllability of CAR T cell therapy.11–14 mRNA-based CAR T cells have already been evaluated in numerous preclinical studies reportingpromisinganti …
A Phase 1 Study of ADI-001: Anti-CD20 CAR- Engineered …
Introduction: ADI-001 is a rst-in-class allogeneic gamma delta ( γδ) CAR T cell therapy targeting the B-cell antigen CD20. ADI-001 has both adaptive and innate cytotoxic eector functions to …
CAR T cell therapy for refractory pediatric systemic lupus ...
CAR T cells were first developed in the 1980s, however, the major clinical breakthrough occurred over 20 years later with the first human trials of anti-CD19 CAR T cells for B cell malignancies …
First-in-Human Trial of CB-010, a CRISPR-Edited Allogeneic …
CB-010: anti-CD19 allogeneic CAR-T cell therapy CB-010 ANTLER Phase 1 trial design Abstract # 3103 First-in-Human Trial of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell …
CD19 and BCMA - Gracell Bio
• CD19-directed CAR-T cell therapy has been demonstrated to be a valuable treatment option for relapsed/refractory B-cell non-Hodgkin’slymphoma (r/r B-NHL) • It has been shown that 39% …
New insights in systemic lupus erythematosus: From …
Sep 20, 2022 · and advanced regulatory T-cell–based cellular therapies. (J Allergy Clin Immunol 2022;150:1289-301.) Keywords: Autoimmunediseases,autoimmunity,CAR-T-celltherapy, cell …
Treatment of Systemic Lupus Erythematosus using BCMA …
autoimmunity, as previous clinical studies using anti-B-cell therapy alone with strategies such as the anti-CD20 antibody Rituximab have been disappointing. While CD19 CAR T cell therapy …
Chimeric Antigen Receptor T -Cell Therapy for B - ICER
Mar 23, 2018 · Chimeric Antigen Receptor T -Cell Therapy for B - Cell Cancers: Effectiveness and Value . Final Evidence Report . March 23, 2018 . Prepared for ... Dr. Andreadis is an …
Prime time session: (HYBRID) Part I: Baby you can drive my car …
CAR-T cell therapy was well-tolerated in these patients. The main questions that now must be addressed are:. Is the abolition of autoreactive B-cell activity permanent?. ... ITY trial, which …
Delivering progress on a cellular level - Bristol Myers Squibb
a CD19-targeted CAR T being investigated to treat forms of lupus and multiple sclerosis. Delivery on a cellular level • So far, we have activated more than 300 ... • Our first-in-class anti-BCMA …
CAR-T in Autoimmune Diseases - Moffitt Cancer Center
B and T cells. • Indefinite Monoclonal antibody therapy results in incomplete control • CAR-T cell therapy mitigates autoimmune diseases by targeting specific markers on B cells (CD19, CD20, …
Potential and pitfalls of repurposing the CAR-T cell regimen …
results with CAR-T cells targeting B cell maturation antigen (BCMA) expressed by plasma cells alone or in combination with CD19.13 14 To date, there have been 6 CAR-T cell therapies …
Treatment of Refractory SLE with Off-the-Shelf iPSC-derived …
iPSC-derived Anti-CD19 CAR T-cell Therapy EULAR European Congress of Rheumatology June 11, 2025 Vaneet K Sandhu, MD, MS ... Systemic lupus erythematosus (SLE), ANCA …
Journal Club: Anti‐CD19 CAR T cell therapy for refractory …
Journal Club: Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Refractory Systemic Lupus Erythematosus Afroditi Boulougoura, Hannah Gendelman, Natalya Surmachevska, and …
Abstracts - lupus.bmj.com
ITY trial, which evaluated obinutuzumab in lupus nephritis (LN), yielded uplifting results.6 The quest for techniques that ... Muller F, Taubmann J, Bucci L, et al. CD19 CAR T-cell therapy in …
Gracell Biotechnologies Presents Longer-Term Results for …
Introduced in 2017, FasTCAR is Gracell's revolutionary next-day autologous CAR-T cell manufacturing platform. FasTCAR is designed to lead the next generation of therapy for …
Feature Nature’s 10 Huji Xu Daring doctor
CAR-T-cell therapy is widely used to treat blood cancers involving malignant B cells, but it has also ... with Xu on a similar trial to treat lupus. “He’s a very knowledgeable physician ...
